Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00136864
Status:
COMPLETED
Last Update Posted:
2011-11-18
First Post:
2005-08-25
Brief Title:
Positron Emission Tomography PET Imaging in Stage III Non-small Cell Lung Cancer PET START Trial
Sponsor:
Ontario Clinical Oncology Group OCOG
Organization:
Ontario Clinical Oncology Group OCOG
Study Overview
Official Title:
The Impact of Positron Emission Tomography PET Imaging in Stage III Non-small Cell Lung Cancer A Prospective Randomized Clinical Trial PET START Trial
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Locally advanced non-small cell lung cancer NSCLC Stage III is potentially curable with aggressive combined modality therapy chemotherapy and radiation Conventional imaging can only evaluate gross anatomic abnormalities but functional imaging with positron emission tomography PET may more accurately identify patients who will benefit from aggressive combined modality therapy
This prospective randomized clinical trial will enroll 400 patients that have undergone conventional staging for lung cancer and have been found to have Stage III NSCLC The patients will then be randomized to either standard combined modality therapy for Stage III NSCLC or to PET imaging prior to combined modality therapy with curative intent Based on the PET findings patients will either be suitable for combined modality therapy with curative intent or not
This prospective randomized clinical trial will enroll 400 patients that have undergone conventional staging for lung cancer and have been found to have Stage III NSCLC The patients will then be randomized to either standard combined modality therapy for Stage III NSCLC or to PET imaging prior to combined modality therapy with curative intent Based on the PET findings patients will either be suitable for combined modality therapy with curative intent or not
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None